These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 16488330)
1. What have we learned in dermatology from the biologic therapies? Nickoloff BJ; Stevens SR J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S143-51. PubMed ID: 16488330 [TBL] [Abstract][Full Text] [Related]
2. Treatment of inflammatory dermatoses with novel biologic agents: a primer. Nussbaum R; Krueger JG Adv Dermatol; 2002; 18():45-89. PubMed ID: 12528402 [No Abstract] [Full Text] [Related]
3. [The treatment of psoriasis: basic principles and new options]. Vereecken P; Provost P; Willaert F; Heenen M; Bentin J Rev Med Brux; 2007 Sep; 28(4):336-44. PubMed ID: 17958030 [TBL] [Abstract][Full Text] [Related]
4. A patient with psoriasis and vitiligo treated with etanercept. Campanati A; Giuliodori K; Ganzetti G; Liberati G; Offidani AM Am J Clin Dermatol; 2010; 11 Suppl 1():46-8. PubMed ID: 20586509 [TBL] [Abstract][Full Text] [Related]
5. Consecutive use of different biological therapies in the treatment of psoriasis. Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044 [No Abstract] [Full Text] [Related]
6. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Sweiss NJ; Curran J; Baughman RP Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312 [TBL] [Abstract][Full Text] [Related]
8. [Biotechnological pharmaceuticals and their potential use in inflammatory skin diseases]. Villadsen L; Baadsgaard O Ugeskr Laeger; 2000 Dec; 162(50):6820-4. PubMed ID: 11187134 [TBL] [Abstract][Full Text] [Related]
9. [What's new in dermatological research?]. Humbert P Ann Dermatol Venereol; 2008 Dec; 135 Suppl 7():S326-34. PubMed ID: 19264208 [TBL] [Abstract][Full Text] [Related]
10. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975 [TBL] [Abstract][Full Text] [Related]
11. Briakinumab. Lima XT; Abuabara K; Kimball AB; Lima HC Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977 [TBL] [Abstract][Full Text] [Related]
12. [Anti-cytokine and anti-lymphocyte monoclonal antibodies in the treatment of thyroid associated ophthalmopathy]. Komorowski J; Jankiewicz-Wika J; Siejka A; Lawnicka H; Stepień H Pol Merkur Lekarski; 2007 Jun; 22(132):571-4. PubMed ID: 17874632 [TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor-alpha as a new therapeutic target for rheumatoid arthritis: an update. Giasuddin AS; Hoque ME; Ahmed ZU Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):88-94. PubMed ID: 17549869 [TBL] [Abstract][Full Text] [Related]
14. Biologic agents in psoriasis. Lee MR; Cooper AJ Australas J Dermatol; 2006 Nov; 47(4):217-29; quiz 229-30. PubMed ID: 17034462 [TBL] [Abstract][Full Text] [Related]
15. Th17 cells: a new therapeutic target in inflammatory dermatoses. Asarch A; Barak O; Loo DS; Gottlieb AB J Dermatolog Treat; 2008; 19(6):318-26. PubMed ID: 18626814 [TBL] [Abstract][Full Text] [Related]
16. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept]. Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of T-cell homing to skin. Hwang ST Adv Dermatol; 2001; 17():211-41. PubMed ID: 11758117 [TBL] [Abstract][Full Text] [Related]
18. Targeted anticytokine therapy and the failing heart. Mann DL Am J Cardiol; 2005 Jun; 95(11A):9C-16C; discussion 38C-40C. PubMed ID: 15925559 [TBL] [Abstract][Full Text] [Related]